Pemphigus Vulgaris (PV) - Epidemiology Forecast to 2027

  • ID: 4520731
  • Report
  • 75 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 3
This report titled ‘Pemphigus Vulgaris (PV) - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Pemphigus Vulgaris in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered:
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

Pemphigus Vulgaris (PV) Epidemiology

The Pemphigus Vulgaris epidemiology division provide the insights about historical and current patient pool and forecasted trend for each of the 7 major countries. The epidemiology data for PV are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Pemphigus Vulgaris Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total prevalent cases, prevalent cases by Severity (Mild, Moderate and Severe), diagnosed and treatable cases] of PV in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to this research, total prevalent population of Pemphigus Vulgaris in 7 major markets was estimated to be 62,747 in 2016.

Report Scope:
  • The report covers detailed overview of PV explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of PV in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by severity of PV in 7MM
Key Strengths:
  • 10 Year Forecast of PV epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of PV
  • Prevalent Cases according to segmentation: PV cases by severity (mild, moderate and severe) in 7MM
  • Diagnosed and treatable cases of PV
Key Assessments:
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Key Insights

2. Disease Background and Overview: Pemphigus Vulgaris (PV)
2.1. Introduction
2.2. Clinical manifestations
2.3. Disease Causes
2.4. PV-Symptoms
2.5. Pathophysiology
2.6. PV Diagnosis
2.6.1. Diagnosis of Pemphigus Vulgaris: Recommendations by an International Panel of Experts

3. Epidemiology and Patient Population
3.1. Key Findings
3.2. Disease Definition
3.3. Population and Forecast Parameters
3.4. 7MM Prevalent Population of Pemphigus Vulgaris (PV)
3.5. 7MM Prevalent Population of PV by Severity

4. Country Wise-Epidemiology of Pemphigus Vulgaris (PV)
4.1. United States
4.1.1. Prevalent cases of PV in the United States
4.1.2. Prevalent cases of PV by severity in the United States
4.1.3. Diagnosed cases of PV in the United States
4.1.4. Treatable cases of PV in the United States
4.2. Germany
4.2.1. Prevalent cases of PV in Germany
4.2.2. Prevalent cases of PV by severity in Germany
4.2.3. Diagnosed cases of PV in Germany
4.2.4. Treatable cases of PV in Germany
4.3. France
4.3.1. Prevalent cases of PV in France
4.3.2. Prevalent cases of PV by severity in France
4.3.3. Diagnosed cases of PV in France
4.3.4. Treatable cases of PV in France
4.4. Italy
4.4.1. Prevalent cases of PV in Italy
4.4.2. Prevalent cases of PV by severity in Italy
4.4.3. Diagnosed cases of PV in Italy
4.4.4. Treatable cases of PV in Italy
4.5. Spain
4.5.1. Prevalent cases of PV in Spain
4.5.2. Prevalent cases of PV by severity in Spain
4.5.3. Diagnosed cases of PV in Spain
4.5.4. Treatable cases of PV in Spain
4.6. United Kingdom
4.6.1. Prevalent cases of PV in the UK
4.6.2. Prevalent cases of PV by severity in the UK
4.6.3. Diagnosed cases of PV in the UK
4.6.4. Treatable cases of PV in the UK
4.7. Japan
4.7.1. Prevalent cases of PV in Japan
4.7.2. Prevalent cases of PV by severity in Japan
4.7.3. Diagnosed cases of PV in Japan
4.7.4. Treatable cases of PV in Japan

5. Appendix

6. Report Methodology
6.1. Sources Used

7. Capabilities

8. Disclaimer

9. About the Publisher

List of Tables
Table 1: Drugs associated with Pemphigus Vulgaris (PV)
Table 2: Differential diagnosis of oral lesions in PV
Table 3: Prevalent Population of PV in the 7MM (2016-2027)
Table 4: 7MM Prevalent Population of PV by severity(2016-2027)
Table 5: Prevalent Cases of PV in the United States (2016-2027)
Table 6: Prevalent Cases of PV in the United States (2016-2027)
Table 7: Diagnosed cases of PV and its Types in the United States (2016-2027)
Table 8: Treatable cases of PV in the United States (2016-2027)
Table 9: Prevalent Cases of PV in Germany (2016-2027)
Table 10: Prevalent Cases of PV by severity in Germany (2016-2027)
Table 11: Diagnosed cases of PV in Germany (2016-2027)
Table 12: Treatable cases of PV in Germany (2016-2027)
Table 13: Prevalent Cases of PV in France (2016-2027)
Table 14: Prevalent Cases of PV by severity in France (2016-2027)
Table 15: Diagnosed cases of PV in France (2016-2027)
Table 16: Treatable cases of PV in France (2016-2027)
Table 17: Prevalent Cases of PV in Italy (2016-2027)
Table 18: Prevalent Cases of PV by severity in Italy (2016-2027)
Table 19: Diagnosed cases of PV in Italy (2016-2027)
Table 20: Treatable cases of PV in Italy (2016-2027)
Table 21: Prevalent Cases of PV in Spain (2016-2027)
Table 22: Prevalent Cases of PV by severity in Spain (2016-2027)
Table 23: Diagnosed cases of PV in Spain (2016-2027)
Table 24: Treatable cases of PV in Spain (2016-2027)
Table 25: Prevalent Cases of PV in the UK (2016-2027)
Table 26: Prevalent Cases of PV by severity in the UK (2016-2027)
Table 27: Diagnosed cases of PV in the UK (2016-2027)
Table 28: Treatable cases of PV in the UK (2016-2027)
Table 29: Prevalent Cases of PV in Japan (2016-2027)
Table 30: Prevalent Cases of PV by severity in Japan (2016-2027)
Table 31: Diagnosed cases of PV in Japan (2016-2027)
Table 32: Treatable cases of PV in Japan (2016-2027)

List of Figures
Figure 1: Clinical manifestations of Pemphigus
Figure 2: Pathogenesis of Pemphigus
Figure 3: Mechanisms of Acantholysis
Figure 4: B-cell and T-cell responses in Pemphigus
Figure 5: a multistep approach for diagnosing PV
Figure 6: Pemphigus Area and Activity Score
Figure 7: Pemphigus Activity Score
Figure 8: Pemphigus Disease Area Index
Figure 9: Pemphigus Vulgaris Lesion Severity Score
Figure 10: Harman's Pemphigus Grading
Figure 11: Kumar's Scoring System
Figure 12: Mahajan's Scoring System
Figure 13: Diagnostic Recommendations for PV by International Panel of Experts
Figure 14: Prevalent Population of PV in 7MM (2016-2027)
Figure 15: 7MM Prevalent Population of PV by severity (2016-2027)
Figure 16: Prevalent cases of PV in the United States (2016-2027)
Figure 17: Prevalent cases of PV by severity in the United States (2016-2027)
Figure 18: Diagnosed Cases of PV in the United States (2016-2027)
Figure 19: Treatable cases of PV in the United States (2016-2027)
Figure 20: Prevalent cases of PV in Germany (2016-2027)
Figure 21: Prevalent cases of PV by severity in Germany (2016-2027)
Figure 22: Diagnosed Cases of PV in Germany (2016-2027)
Figure 23: Treatable cases of PV in Germany (2016-2027)
Figure 24: Prevalent cases of PV in France (2016-2027)
Figure 25: Prevalent cases of PV by severity in France (2016-2027)
Figure 26: Diagnosed Cases of PV in France (2016-2027)
Figure 27: Treatable cases of PV in France (2016-2027)
Figure 28: Prevalent cases of PV in Italy (2016-2027)
Figure 29: Prevalent cases of PV by severity in Italy (2016-2027)
Figure 30: Diagnosed Cases of PV in Italy (2016-2027)
Figure 31: Treatable cases of PV in Italy (2016-2027)
Figure 32: Prevalent cases of PV in Spain (2016-2027)
Figure 33: Prevalent cases of PV by severity in Spain (2016-2027)
Figure 34: Diagnosed Cases of PV in Spain (2016-2027)
Figure 35: Treatable cases of PV in Spain (2016-2027)
Figure 36: Prevalent cases of PV in the UK (2016-2027)
Figure 37: Prevalent cases of PV by severity in the UK (2016-2027)
Figure 38: Diagnosed Cases of PV in the UK (2016-2027)
Figure 39: Treatable cases of PV in the UK (2016-2027)
Figure 40: Prevalent cases of PV in Japan (2016-2027)
Figure 41: Prevalent cases of PV by severity in Japan (2016-2027)
Figure 42: Diagnosed Cases of PV in Japan (2016-2027)
Figure 43: Treatable cases of PV in Japan (2016-2027)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll